Insmed has reported preliminary sales results for its new bronchiectasis drug Brinsupri, showing revenue of $144.6 million in the fourth quarter of 2025. This figure is nearly three times higher than analyst expectations, which had forecasted $57.6 million for the period.
Analysts at William Blair described the outcome as a “blowout sales performance,” noting that they have “increased confidence in the drug’s multi-blockbuster sales potential long-term.” Guggenheim Partners also commented on the results, stating, “$144.6M??” and adding that this amount surpassed even the $75 million “that we believe the buyside was hoping to see.”
The strong sales were attributed to 9,000 new patients starting Brinsupri in the fourth quarter, supplementing about 2,550 patients who began treatment during its launch in the previous quarter. Analysts at Truist estimated that approximately 11,500 patients are now using Brinsupri, which is ahead of their projections for patient growth.
Brinsupri received FDA approval in August 2025 for daily use in adults and children aged 12 and older with non-cystic fibrosis bronchiectasis. At launch, analysts from Guggenheim projected that annual sales could reach $7.3 billion by 2033. Insmed estimates there are around 500,000 potential patients for Brinsupri in the United States. The drug’s annual cost is set at $88,000.
In addition to Brinsupri’s performance, Insmed reported that its inhalable mycobacterium antibiotic Arikayce exceeded guidance with $433.8 million in annual revenue. The company had previously raised its guidance for Arikayce from a range of $405 million–$425 million to $420 million–$430 million due to better-than-expected sales throughout the year.
Shares of Insmed rose about 8% to $183.80 following these announcements.
